Zhenyi Medical Secures Hundreds of Millions in Series C Funding to Advance Cardiovascular Intervention Platform and Files IPO Prospectus

Recently, Jiangsu Trulive Medtech Co., Ltd. (hereinafter referred to as "Trulive") announced the completion of a C-round financing worth hundreds of millions of yuan. This round of financing was jointly invested by Oriental Fortune, Guoyuan Direct Investment, Xiamen Industrial Investment/Venture Capital, Bozheng Capital, Xiamen Gold Innovation, and Siming Sci-Tech Innovation, with continued support from existing shareholder Life Tree Capital.

This is another round of key financing completed by Trulive in recent years. The continuous investment from capital reflects the market's high recognition of the company’s platform-based layout, technological innovation capabilities, and commercialization prospects. It also marks a new phase in the breakthrough of China-produced cardiovascular intervention enterprises in the high-end device field.

With the accelerating aging process of China's population, the incidence of valvular heart disease, heart failure, and peripheral vascular diseases continues to rise. Traditional open-chest surgeries are highly invasive, have slow recovery times, and are unfriendly to elderly or high-risk patients, making it urgent for the clinical field to adopt safer, minimally invasive, and repeatable interventional treatment options.

In recent years, interventional treatment for structural heart disease, represented by transcatheter mitral and tricuspid valve repair and replacement, has become an important innovative direction in the global cardiovascular field. However, for a long time, high-end valve interventional devices have been monopolized by multinational giants, with a very low rate of domestically produced alternatives, leaving a significant gap in the Chinese market and unmet clinical needs.

Against this backdrop, Trulive has taken the lead in focusing on the "blood flow management" track, providing Chinese patients with more accessible and precise treatment options through technological innovation and systematic layout.

Trulive, established in 2019, focuses on the field of cardiovascular diseases with extremely high mortality and disability rates where domestically produced products are still absent. Its business comprehensively covers four major disease areas: heart valves, heart failure, peripheral vascular, and coronary artery, making it the first domestic platform-based high-end medical device company in China to fully cover these four golden tracks with all core products achieving substantial progress.

Since its establishment, the company has maintained a rapid growth pace, achieving financing rounds for several consecutive years. After completing the B+ round of financing in 2023, the company’s R&D, registration, and clinical progress have accelerated comprehensively. The success of this C round of financing provides solid support for its entry into the scaled commercialization and international expansion phase.

Trulive's core competitiveness lies in its multi-technology pathway product system, covering several key directions such as valve repair, valve replacement, and vascular access intervention.

Trulive Chairman Wen Jing stated that this round of financing is an important milestone for the company as it moves into a new phase. In the future, the company will use the funds as a driving force to focus on advancing the following strategies:

• Build a National R&D and Manufacturing Network: With Shanghai as the R&D core, establish a high-end production cluster in the Yangtze River Delta, and build research and manufacturing bases in key regions to achieve multi-center collaboration.

• Strengthening Clinical and Educational Systems: Relying on high-quality hospital resources in China, a professional training center will be established to promote the standardized adoption of valve interventional technology.

• Deepen International Cooperation: Actively connect with global clinical resources, explore joint R&D and overseas expansion models, and promote China's original technologies to the world.

Investors such as Eastern Fortune Sea, Guoyuan Direct Investment, and Xiamen Industrial Investment all expressed optimism about Trulive's continuous growth potential in technological leadership, product pipeline completeness, and commercial execution.

Investors believe that Trulive's strategy of "one step ahead in technology, half a step ahead in business" has established a clear competitive barrier in the field of structural heart disease in China and possesses the long-term value to become an industry benchmark.

The completion of this Series C financing round is not only a critical milestone for Trulive's development but also reflects the accelerating maturity of China's structural heart disease interventional treatment sector.

Starting from clinical needs, Trulive is building up full-chain capabilities from technological innovation, clinical validation to commercialization through systematic R&D and platform-based integration. As multiple core products are about to enter the registration and market launch phase, China-produced high-end interventional devices are ushering in an unprecedented window of opportunity.

In the future, Trulive will continue to uphold the concept of "defining standards through technology and creating value through innovation." With the dual impetus of capital and industry, it aims to provide safer, more efficient, and affordable treatment solutions for more patients with cardiovascular diseases, propelling China's interventional treatment industry towards the higher end of the global value chain.

This article is a reprint. If there are any information errors or infringement issues, please feel free to contact the author for handling and removal. Thank you!